openPR Logo
Press release

The Hyper IgM Foundation Presents $5,000 Grant to Dr. Caroline Kuo at UCLA

07-06-2017 10:00 AM CET | Health & Medicine

Press release from: Hyper IgM Foundation

For Immediate Release
July 6, 2017

NEW YORK, New York—The Hyper IgM Foundation is delighted to announce it has awarded $5,000 to Dr. Caroline Kuo and the Regents of the University of California, Los Angeles, to support research in connection with Site-Specific Gene Editing in the Treatment of X-Linked Hyper-IgM Syndrome.

These funds will support the continued work in search of curative treatment for X-Linked Hyper IgM Syndrome (X-HIGM). Currently, the only known cure for X-HIGM is a stem cell transplant. There are no curative treatment options, however, for those X-HIGM patients without an HLA match or those with chronic infections or other conditions that make allogeneic stem cell transplant too risky. Graft rejection and graft-versus-host disease in patients following a stem cell transplant remain major issues for patients. Dr. Kuo plans to use the grant to further perfect the use of stem cell manipulation without the need for a donor. What this means is a transplant of the patient’s own, gene-corrected stem cells after having undergone site-specific stem cell gene therapy. In turn, there should be no rejection from the host, being that the cells are recognized as same DNA.

In the next year (July 1, 2017 to June 30, 2018), the funding from the grant will help cover continued work and ensure that site-specific gene editing in human stem cells can be long-lasting and self-renewing. In other words, if doctors can fix the defective gene in the stem cell and give it back to the patient, the hope is that the now-corrected stem cell will give rise to normal T-cells that efficiently express CD40 Ligand for the rest of the patient’s life — leading to full immune response for the individual.

The proposal reads, “These experiments set the foundation for a promising therapy for patients with X-linked Hyper IgM Syndrome.” Hyper IgM affects only 1 in 1,000,000 individuals. The life-threatening genetic mutation severely compromises the immune system and its ability to produce responses to pathogens such as bacteria and viruses. The Hyper IgM Foundation’s mission is to improve the treatment, quality of life and long-term outlook for children and adults living with Hyper IgM.

The Foundation gives families coping with Hyper IgM the opportunity to connect with other patient families to gain both knowledge and support.

The Hyper IgM Foundation also fundraises all year long in order to fund progress in research for a cure. Last year alone, the foundation raised over $40,000. The goal is to see this gene-editing treatment moved forward into clinical trials, and that is where help is needed.

For more information about Hyper IgM Syndrome or to support the cause please visit www.hyperigm.org/donate.

If you have any questions or interest in supporting our foundation, please email info@hyperigm.org.

Hyper IgM Foundation, a non-profit organization, was founded in 2015 by dedicated parents, healthcare professionals and friends. Our mission is to improve the treatment, quality of life and the long term outlook for children and adults living with Hyper IgM through research, support, education, and advocacy to families and patients.

Hannah Ross
The Hyper IgM Foundation
215 W 101st, Suite 7B
New York, New York
Phone: 646-883-4446
Email: info@hyperigm.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Hyper IgM Foundation Presents $5,000 Grant to Dr. Caroline Kuo at UCLA here

News-ID: 610766 • Views:

More Releases from Hyper IgM Foundation

The Hyper IgM Foundation Awards $100,000 Grant to Dr. Daniele Canarutto and Prof …
NEW YORK, New York-The Hyper IgM Foundation is thrilled to announce it has awarded $100,000 to Dr. Daniele Canarutto and Prof. Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy to support groundbreaking research into In-depth genome integrity characterization of CD4+ T-cells gene-edited at the CD40LG locus for the treatment of Hyper-IgM 1. Hyper IgM Foundation President, Akiva Zablocki, expressed, "This marks the largest research
Hyper IgM Foundation Research Grants:
FOR IMMEDIATE RELEASE: January 11 , 2017. The Hyper IgM Foundation is proud to announce the availability of seed grant funding for researchers interested in the advancement of a cure for Hyper IgM Syndrome and primary immunodeficiency disorders. The intent of these grants is to accelerate scientific work focused on improving the treatment, quality of life, and long-term outlook for patients with Hyper IgM. Special consideration will be given to well-defined

More Releases for Syndrome

Hunter Syndrome Treatment Market Size, Share | Hunter Syndrome Treatment Industr …
Global Hunter Syndrome Treatment Market Report provides a detailed industry overview along with the analysis of Cost Structure, Supply Chain, Development Techniques, Retailers Analysis, Financial Support, business Strategies, Marketing Channels. Global Hunter Syndrome Treatment Market research report provides a point-by-point In-Depth analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain
03-27-2018 | Health & Medicine
GBSCIDP
GBS GBS in Canada Guillain Barre Syndrome in Canada Guillain Barre Syndrome
What is Guillain-Barre Syndrome (GBS)? Guillain-Barré (Ghee-yan Bah-ray) Syndrome is an intemperate disorder of the incidental nerves outside the brain and spinal cord. GBS also called: 1. Acute Incendiary Demyelinating Polyneuropathy 2. Landry’s Ascending Paralysis GBS is indicate by the rapid onset of numbness, weakness, and often paralysis of the legs, arms, breathing muscles, and face. Deflation is climbing meaning that
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape. Gorlin syndrome, also known as nevoid
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017
ReportsWeb.com published “Gorlin Syndrome Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Original Content: Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape. Gorlin
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syn …
Global Markets Directs, Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and
Complex Regional Pain Syndrome
“Complex Regional Pain Syndrome Global 2016 Clinical Trials Review, H2" provides an detailed overview of Complex Regional Pain Syndrome scenario. Report includes top line data relating on Complex Regional Pain Syndrome Global clinical trials scenario. This report on Complex Regional Pain Syndrome also includes an review of trial numbers as well as their ( Complex Regional Pain Syndrome ) average enrollment in uppermost/top countries which are conducted worldwide. Complex Regional